Biological materials management and standards organization ATCC has secured a potential 10-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract award from the Biomedical Advanced Research and Development Authority (BARDA).
The agreement, which possesses a ceiling value of $250 million, complements ATCC’s ongoing support of the government’s COVID-19 pandemic response with BARDA, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, and the Food and Drug Administration.
The effort calls for ATCC to provide the BARDA Clinical Studies Network (CSN) with a biological specimen and investigational product storage facility with centralized services for collection, receipt, storage, protection, processing, tracking, retrieval, packaging, and distribution.
“This program enhances and extends ATCC’s long history as a national resource supporting both American competitiveness in basic and clinical science and critical public health efforts,” Dr. Raymond H. Cypess, chairman and CEO of ATCC, said. “ATCC is a partner in the investigations of the academic, government, and commercial research communities to develop effective diagnostic, therapeutic, and preventive tools and reagents. We look forward to supporting BARDA and the Clinical Studies Network to improve the health and safety of our nation.”
Joseph Leonelli, vice president of ATCC Federal Solutions, said with the award, ATCC continues to expand its support for the Department of Health and Human Services (HHS) and critical government clinical studies on vaccines, diagnostics, and therapeutics.